Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment

计划入组 90 人 · 首次发布于 2026 年 6 月 9 日

S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation

计划入组 80 人 · 首次发布于 2026 年 7 月 23 日

Management of Robertsonian Translocation PGT-SR Attempts

计划入组 148 人 · 首次发布于 2021 年 11 月 5 日

GSK-4023991

PCSK9 translation inhibitors (Pfizer)

RSV translation inhibitors (RSV infection)

Canadian Medical and Surgical Knowledge Translation Research Group

Canada

FDA Approves Revuforj (revumenib) for R/R Acute Leukemia with KMT2A Translocation

Revumenib Demonstrates Sustained Responses in Relapsed/Refractory KMT2Ar Acute Leukemia

FDA Approves Revumenib for Relapsed/Refractory Acute Leukemia with KMT2A Translocation